Business
The Oncology Institute Reaffirms 2025 Guidance and Provides Preliminary 2026 Outlook
CERRITOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided its preliminary 2026 outlook. 2026 Outlook For 2026, TOI anticipates that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges, and including approximately $150 million of Capita
About this update from The Oncology Institute, Inc.
[{"type":"image","alt":"TOI Management, LLC","displaySize":"","headline":null,"caption":"TOI Management, LLC","className":"","disableSlideshowImg":false,"size":{"original":{"width":248,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/38271848c3d8a5e1e22cde43512eba2e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yhdVXLCOU06mfTSW3.iIsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/38271848c3d8a5e1e22cde43512eba2e","width":248,"height":86}},"lazy":false},{"type":"text","content":"CERRITOS, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based oncology groups in the United States, today reaffirmed 2025 guidance and provided its preliminary 2026 outlook.","length":263,"tagName":"p"},{"type":"text","content":"2026 Outlook","length":12,"tagName":"p"},{"type":"text","content":"For 2026, TOI anticipates that total revenue will be in the range of $630 million to $650 million, reflecting 28% growth from the midpoint of 2025 and 2026 guidance ranges, and including approximately $150 million of Capitation revenue in 2026. This expected top-line increase reflects continued expansion of delegated contracts in Florida, the annualized impact of strong volumes in the Dispensary segment during the second half of 2025, and broader organic growth and new contract wins across the platform. While these drivers are expected to contribute meaningfully to revenue in 2026, the Company anticipates profitability from newly onboarded delegated contracts to build progressively over the course of the year, with more fully realized economics in 2027.","length":763,"tagName":"p"},{"type":"text","content":"Based on these factors, and inclusive of targeted investments to support TOI’s ongoing growth, we expect Adjusted EBITDA for 2026 to be in the range of $0 million to $9 million. At the midpoint of this range, 2026 would represent TOI’s first full year of Adjusted EBITDA profitability as a public company.","length":305,"tagName":"p"},{"type":"text","content":"TOI uses Adjusted EBITDA, a non-GAAP metric, as an additional tool to assess its operational and financial performance. See "Financial Information: Non-GAAP Financial Measures" below. In reliance on the unreasonable efforts exception provided under Regulation S-K, T...